Similarly, a report by Sheng et al. 30 suggested that NSCLC patients with EGFR exon 19 deletion had a longer PFS and OS, and a higher response rate after EGFR-TKI therapy compared with those with exon 21 L858R mutation. Here, EGFR is linked to non-small cell lung carcinoma.